Pancreatic Cancer

The FDA accepted Revolution Medicines’ NDA for oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The filing is supported by RASolute 302, where median overall survival was 13.2 months versus 6.7 months with…